UNSPSC 51111854: Nafarelin

This classification denotes a gonadotropin-releasing hormone analog with the molecular formula C66H83N17O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1X0094V6JV, chemically known as luteinizing hormone-releasing factor (pig), 6-(3-(2-naphthalenyl)-d-alanine)- but generally known as nafarelin, which bears US NIH Compound Identifier 16129618. European Medicines Agency schedules Nafarelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09115MIG.

UNSPSC 51111854 Nafarelin, a Commodity code, covers pharmaceutical active ingredients and finished-dose medications supplied to state and local health systems. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 to establish multi-award contracts for generic pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. MMCAP procures through a three-wholesaler model—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—requiring manufacturers to submit detailed product specifications including National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, and manufacturing locations. Vendor evaluation weights pricing competitiveness at 75 percent, with secondary criteria covering fixed pricing (10 percent), administrative compliance and EDI capability (5 percent each), and agreement to a 3 percent administrative fee (5 percent). Vendors must hold $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability insurance, certify current Good Manufacturing Practices and Drug Supply Chain Security Act compliance, and maintain chargeback relationships with at least two of the three authorized wholesalers.

The single recent opportunity shows activity concentrated in the multistate cooperative purchasing channel serving state Medicaid and local health departments. Proposals were due March 26, 2026 with a February 18, 2026 Q&A cutoff; awarded vendors become effective July 1, 2026 and commit to an initial two-year contract term with optional extensions. MMCAP explicitly reserves multi-award discretion based on therapeutic considerations, product availability, and member-specific needs, signaling an open competitive environment without preset set-aside restrictions. No specific dollar value is disclosed, and the source does not indicate whether this code has sustained activity beyond the single MMCAP solicitation or activity in other states and local jurisdictions outside the cooperative channel.